This is Part II of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial.
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy’s life, is one of the deadliest brain tumors that can occur in both adults and children.
Copyright © 2025 | WordPress Theme by MH Themes